Noopur S. Raje, MD

The panel debates the options for treatment of late relapsed multiple myeloma.

Drs Hana Safah and Krina Patel share data from key clinical trials investigating the treatment of relapsed multiple myeloma.

Dr Amrita Krishnan explains the difference between biochemical and clinical relapse in multiple myeloma.

Noopur Raje, MD, details the data on treatment duration in older patients with multiple myeloma and transplant-eligible patients.

Amrita Krishnan, MD, and Hana Safah, MD, discuss how to measure frailty in patient with multiple myeloma.

Hana Safah, MD, explains the common treatment approaches for patients with transplant-ineligible multiple myeloma.

Sagar Lonial, MD, introduces the expert panel and starts a conversation on data updates in the treatment of transplant-eligible multiple myeloma.

Noopur Raje, MD, discusses the utilization of bb21217 in patients with relapsed/refractory in multiple myeloma.

Noopur Raje, MD, discusses current CAR T-cell therapies in multiple myeloma.

Noopur Raje, MD, discusses unmet needs with CAR T-cell therapy in multiple myeloma.

Noopur S. Raje, MD, discusses recent findings with melflufen in relapsed/refractory multiple myeloma.

Noopur S. Raje, MD, discusses remaining questions in multiple myeloma. 

Noopur S. Raje, MD, discusses the quadruplet therapies that are currently available for patients with multiple myeloma.

Noopur S. Raje, MD, discusses the ​design of the randomized phase 3 E​NDURANCE trial in ​newly diagnosed multiple myeloma.

Noopur S. Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, and professor of medicine, Harvard Medical School, highlights the different options available for patients with relapsed multiple myeloma.